Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

More Biosimilars Marketed in Germany, Switzerland Than U.S.

admin by admin
December 4, 2022
in News


FRIDAY, Dec. 2, 2022 (HealthDay News) — More biosimilars have been marketed in Germany and Switzerland than in the United States, but uptake has increased over time in all countries, according to a study published online Dec. 2 in JAMA Network Open.

David L. Carl, from the University of Zurich, and colleagues examined uptake and prices of biosimilars in the United States versus Germany and Switzerland in a cohort study. For 2011 to 2020, prices and sales data were extracted from public and commercial databases.

The study cohort included 15 biosimilars and six biologics for the United States; 52 and 15 for Germany; and 28 and 13 for Switzerland. The researchers found that in all countries, uptake of biosimilars increased over time. On average, the highest biosimilar market share at launch was seen in Germany; however, in the United States, it increased at the fastest rate. Monthly treatment costs of biosimilars were a median of 1.94 and 2.74 higher in the United States versus the corresponding costs in Germany and Switzerland.

“Policies for drug pricing negotiations in the United States against anticompetitive practices of exclusionary contracts could allow biosimilars to enter the market sooner and at lower costs, which could result in lower health care costs and improved patient access,” the authors write. “Awareness of biosimilars should be promoted to increase the uptake of biosimilars in all three countries.”

Abstract/Full Text

Copyright © 2022 HealthDay. All rights reserved.
healthday



Source link

Advertisement Banner
Previous Post

Airway Management of Patients in Hospice and Palliative Care

Next Post

‘Breaking Down Interstate Barriers to Telehealth Delivery’ Tops ATA’s Priorities for 2023 – The Health Care Blog

Related Posts

News

Treatment of Older Adults’ Constipation Caused by Opioids

February 7, 2023
News

Serious Illness: Advance Care Planning

February 6, 2023
News

Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality

February 5, 2023
News

#VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension

February 4, 2023
News

Risk of Severe COVID-19 Infection and Other SARIs in Preexisting Neuropsychiatric Conditions

February 3, 2023
News

Vitiligo Responding and Refractory Alopecia Areata During the Monotherapy With Tofacitinib

February 2, 2023
Next Post

‘Breaking Down Interstate Barriers to Telehealth Delivery’ Tops ATA’s Priorities for 2023 – The Health Care Blog

Recommended

Clover Health drops ACO REACH participation in 2023

3 months ago

CMS increases ESRD facilities 2023 payment

3 months ago

Metformin and Survival in Diabetes-related In-hospital Cardiac Arrest

2 months ago

Congenital AoV Lesions Repair with AP Vs. Porcine Intestinal Submucosa

3 months ago

With access to my records, I took my business elsewhere – The Health Care Blog

4 days ago

© 2022 Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.